

Clinical trials of immune checkpoint inhibition for lung cancer (metastatic) in first line

TrialResults-center www.trialresultscenter.org

1 PD-L1 inhibitors

Trial	Treatments	Patients	Trials design and methods
atezolizumab + platinum-based CT vs platinum-based CT			
IMpower 132 <i>ongoing</i> [NCT02657434] n=NA follow-up:	Atezolizumab + Carboplatin or Cisplatin + Pemetrexed versus Carboplatin or Cisplatin + Pemetrexed)	Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)	Open Label
IMpower 133 <i>ongoing</i> [NCT02763579] n=NA follow-up:	Atezolizumab + Carboplatin + Etoposide versus Placebo + Carboplatin + Etoposide	Participants With Untreated Extensive-Stage Small Cell Lung Cancer	Participant, Investigator

References

IMpower 132, :

IMpower 133, :

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.